ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Linagliptin

Also written as “BI 1356”, “linagliptin” and “Linagliptin/Metformin FDC”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus · Esophageal Neoplasms · Carcinoma, Non-Small-Cell Lung · Hypertension, led by 7 companies.

Drug pageLinagliptin: every studyMany companies study it; this page follows only the 89 they lead. All 129 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 21, 201189 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheimits history only800 open or runningphase 4since Sep 21, 2011Mar 31, 2006none ahead
Dong Wha Pharmaceuticalits history only30 open or runningphase 1since Aug 6, 2014Aug 6, 2014none ahead
Profil Institut für Stoffwechselforschungits history only20 open or runningphase 4since Jul 11, 2013Jul 11, 2013none ahead
Genuine Research Center, Egypt10 open or runningphase 1since Aug 3, 2016Aug 3, 2016none ahead
ikfe-CROits history only10 open or runningphase 3since Feb 11, 2015Feb 11, 2015none ahead
Marcus Borchertits history only10 open or runningphase 4since Feb 21, 2012Feb 21, 2012none ahead
Nabiqasim Industries (Pvt)its history only11 open or runningphase 4since Feb 19, 2025Feb 19, 2025none ahead

Also a collaborator on its studies: Halozyme Therapeutics, BioLineRx, Eli Lilly, Eva Pharma, Ikfe and MLM Medical Labs.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Genuine Research Center, Egypt only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 3, 2016First study: phase 1 study in HealthyFirst studyNCT02857946 · 24 enrolled · Egypt

TargetBeta

DPP4 →read by rule
“A potent, orally bioavailable dihydropurinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity”NCIt, by rule
“Dipeptidyl peptidase IV inhibitor”ChEMBL 37, by rule

Other programs on DPP4

ProgramCompanyFurthest phaseStudies
sitagliptinruleMerckphase 4123
gemigliptinruleLG Chemphase 430
anagliptinruleJW Pharmaceuticalphase 46
Empagliflozin/LinagliptinruleHumanis Saglık Anonim Sirketiphase 12
cofrogliptinruleHaisco Pharmaceutical Groupno phase1

Studies

The one study Genuine Research Center, Egypt leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02857946Healthy · Egypt1CompletedMar 201624

How it is read

Names in the registry

  • “Linagliptin”, 35 entries
  • “BI 1356”, 14 entries
  • “linagliptin”, 10 entries
  • “Linagliptin/Metformin FDC”, 4 entries
  • “BI 1356 BS”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.